Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 2/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.39 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ATR | Q13535 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | PTGES | O14684 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7014676 | 0.84 | PTGES (0.40) | GRM2GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL8804904 | 0.84 | ESR2 (0.44) | GRM2GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL9432764 | 0.84 | ALOX5AP (0.41) | GRM2GABRG2GABRB3GABRA5GABRA3 | |
| Bromide SCHEMBL9121443 | 0.83 | ALOX5AP (0.40) | GRM2GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL27883850 | 0.82 | PTGES (0.38) | GRM2GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL8965456 | 0.81 | ALDH1A1 (0.39) | GABRG2GABRB3GABRA5GABRA3ALOX5AP | |
| SCHEMBL10470846 | 0.79 | RAB9A (0.49) | L3MBTL1GAAALDH1A1HPGDTDP1 | |
| SCHEMBL27932263 | 0.79 | CYP11B1 (0.47) | GABRG2GABRB3GABRA5GABRA3CYP3A4 | |
| SCHEMBL28371929 | 0.76 | PTGES (0.52) | GABRG2GABRB3GABRA5GABRA3ALOX5AP | |
| SCHEMBL7015125 | 0.76 | CCR1 (0.50) | GRM2GABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9115136-B2 | Fused ring compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-25 | — | — | US | disclosed |
| US-8921379-B2 | Fused ring compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-30 | — | — | US | disclosed |
| CN-102369205-B | fused ring compound and use thereof | TAKEDA PHARMACEUTICAL CO.,LTD. (JP) | 2014-10-29 | — | — | CN | disclosed |
| CN-103788097-A | Fused ring compound and application thereof | TAKEDA PHARMACEUTICAL | 2014-05-14 | — | — | CN | disclosed |
| US-20140046056-A1 | FUSED RING COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-02-13 | — | — | US | disclosed |
| US-8592431-B2 | Fused ring compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-26 | — | — | US | disclosed |
| EP-2384327-B1 | FUSED RING COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2013-07-31 | — | — | EP | disclosed |
| US-8283353-B2 | Fused ring compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-09 | — | — | US | disclosed |
| CN-102369205-A | Fused ring compound and use thereof | TAKEDA PHARMACEUTICAL | 2012-03-07 | — | — | CN | disclosed |
| US-20110294832-A1 | FUSED RING COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-12-01 | — | — | US | disclosed |
| CN-1175414-A | Method for preparing substd. azacyclopyrimidine compound, its pharmaceutic salt or N-oxide | AMERICAN HOME PROD (US) | 1998-03-11 | — | — | CN | disclosed |
| EP-0539086-B1 | Condensed pyrimidine derivatives and their use as angiotensine II antagonists | AMERICAN HOME PROD (US) | 1997-12-29 | — | — | EP | disclosed |
| US-5498776-A | Substituted pyrrolopyrimidines and pyridopyrimidines useful as angiotensin II antagonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-03-12 | — | — | US | disclosed |
| US-5451583-A | Angiotensin inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-09-19 | — | — | US | disclosed |
| WO-1994011365-A1 | SUBSTITUTED BENZIMIDAZOLES AND QUINAZOLINES AS ANTIHYPERTENSIVES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1994-05-26 | — | — | WO | disclosed |
| US-5283242-A | Hypotensive agents, cardiotonic agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1994-02-01 | — | — | US | disclosed |
| US-5256654-A | Substituted pyrrolopyrimidines, azepinopyrimidines and pyridopyrimidines useful as angiotensin II antagonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 1993-10-26 | — | — | US | disclosed |
| CN-1072682-A | SUBSTITUTED PYRIMIDINES | AMERICAN HOME PROD (US) | 1993-06-02 | — | — | CN | disclosed |
| EP-0539086-A2 | Condensed pyrimidine derivatives and their use as angiotensine II antagonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 1993-04-28 | — | — | EP | disclosed |
| US-5149699-A | Substituted pyridopyrimidines useful as antgiotensin II antagonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140046056-A1 | FUSED RING COMPOUND AND USE THEREOF | PPARA, PPARG, AGTR2 | GRM2 195/4885GABRG2 337/4885GABRB3 262/4885 |
| US-20110294832-A1 | FUSED RING COMPOUND AND USE THEREOF | PPARA, PPARG, AGTR2 | GRM2 195/4885GABRG2 337/4885GABRB3 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.